In Silico Design of Potential Small-Molecule Antibiotic Adjuvants against <i>Salmonella typhimurium</i> Ortho Acetyl Sulphydrylase Synthase to Address Antimicrobial Resistance

• Main Authors: Oluwadunni F. Elebiju (Author), Gbolahan O. Oduselu (Author), Temitope A. Ogunnupebi (Author), Olayinka O. Ajani (Author), Ezekiel Adebiyi (Author)
• Format: Book
• Published: MDPI AG, 2024-04-01T00:00:00Z.
• Subjects: article
• Online Access: Connect to this object online.
• Notes: 10.3390/ph17050543; 1424-8247
• Keywords: adjuvants; antibiotics; cysteine biosynthesis; <i>St</i>OASS; drug resistance; scaffold hopping; Medicine; R; Pharmacy and materia medica; RS1-441
• Source: Pharmaceuticals, Vol 17, Iss 5, p 543 (2024)

The inhibition of <i>O</i>-acetyl sulphydrylase synthase isoforms has been reported to represent a promising approach for the development of antibiotic adjuvants. This occurs via the organism developing an unpaired oxidative stress response, causing a reduction in antibiotic resistance in vegetative and swarm cell populations. This consequently increases the effectiveness of conventional antibiotics at lower doses. This study aimed to predict potential inhibitors of <i>Salmonella typhimurium</i> ortho acetyl sulphydrylase synthase (<i>St</i>OASS), which has lower binding energy than the cocrystalized ligand pyridoxal 5 phosphate (PLP), using a computer-aided drug design approach including pharmacophore modeling, virtual screening, and in silico ADMET (Absorption, Distribution, Metabolism, Excretion, and Toxicity) evaluation. The screening and molecular docking of 4254 compounds obtained from the PubChem database were carried out using AutoDock vina, while a post-screening analysis was carried out using Discovery Studio. The best three hits were compounds with the PubChem IDs 118614633, 135715279, and 155773276, possessing binding affinities of −9.1, −8.9, and −8.8 kcal/mol, respectively. The in silico ADMET prediction showed that the pharmacokinetic properties of the best hits were relatively good. The optimization of the best three hits via scaffold hopping gave rise to 187 compounds, and they were docked against <i>St</i>OASS; this revealed that lead compound <b>1</b> had the lowest binding energy (−9.3 kcal/mol) and performed better than its parent compound 155773276. Lead compound <b>1</b>, with the best binding affinity, has a hydroxyl group in its structure and a change in the core heterocycle of its parent compound to benzimidazole, and pyrimidine introduces a synergistic effect and consequently increases the binding energy. The stability of the best hit and optimized compound at the <i>St</i>OASS active site was determined using RMSD, RMSF, radius of gyration, and SASA plots generated from a molecular dynamics simulation. The MD simulation results were also used to monitor how the introduction of new functional groups of optimized compounds contributes to the stability of ligands at the target active site. The improved binding affinity of these compounds compared to PLP and their toxicity profile, which is predicted to be mild, highlights them as good inhibitors of <i>St</i>OASS, and hence, possible antimicrobial adjuvants.